| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Androgen Antagonists | 75 | 2022 | 1377 | 8.750 |
Why?
|
| Prostatic Neoplasms | 161 | 2018 | 11124 | 8.480 |
Why?
|
| Gonadotropin-Releasing Hormone | 47 | 2015 | 1205 | 5.940 |
Why?
|
| Bone Neoplasms | 55 | 2019 | 2529 | 5.610 |
Why?
|
| Antineoplastic Agents, Hormonal | 48 | 2017 | 1524 | 5.540 |
Why?
|
| Diphosphonates | 41 | 2016 | 623 | 4.960 |
Why?
|
| Bone Density Conservation Agents | 37 | 2016 | 773 | 4.780 |
Why?
|
| Leuprolide | 13 | 2015 | 321 | 3.100 |
Why?
|
| Orchiectomy | 29 | 2015 | 474 | 3.070 |
Why?
|
| Toremifene | 10 | 2013 | 24 | 3.060 |
Why?
|
| Anilides | 13 | 2016 | 408 | 2.910 |
Why?
|
| Imidazoles | 24 | 2016 | 1206 | 2.870 |
Why?
|
| Osteoporosis | 31 | 2012 | 1580 | 2.740 |
Why?
|
| Prostate-Specific Antigen | 36 | 2018 | 2494 | 2.100 |
Why?
|
| Phenylthiohydantoin | 5 | 2017 | 193 | 2.090 |
Why?
|
| RANK Ligand | 10 | 2013 | 326 | 1.820 |
Why?
|
| Bone Density | 28 | 2012 | 3468 | 1.520 |
Why?
|
| Prednisone | 15 | 2019 | 1574 | 1.510 |
Why?
|
| Antineoplastic Agents | 32 | 2022 | 13695 | 1.410 |
Why?
|
| Fractures, Bone | 19 | 2019 | 1947 | 1.370 |
Why?
|
| Neoplasms, Hormone-Dependent | 12 | 2014 | 415 | 1.310 |
Why?
|
| Thiohydantoins | 2 | 2018 | 20 | 1.220 |
Why?
|
| Body Composition | 12 | 2014 | 2401 | 1.210 |
Why?
|
| Osteoclasts | 9 | 2012 | 729 | 1.200 |
Why?
|
| Nitriles | 13 | 2017 | 956 | 1.180 |
Why?
|
| Androgen Receptor Antagonists | 4 | 2016 | 114 | 1.140 |
Why?
|
| Goserelin | 5 | 2015 | 129 | 1.090 |
Why?
|
| Adenocarcinoma | 11 | 2014 | 6364 | 1.050 |
Why?
|
| Pyridines | 6 | 2016 | 2825 | 0.950 |
Why?
|
| Bone and Bones | 14 | 2014 | 2575 | 0.940 |
Why?
|
| Male | 196 | 2022 | 350118 | 0.940 |
Why?
|
| Tosyl Compounds | 7 | 2008 | 113 | 0.890 |
Why?
|
| Double-Blind Method | 27 | 2021 | 12026 | 0.850 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2022 | 11524 | 0.820 |
Why?
|
| Prostatectomy | 13 | 2016 | 1890 | 0.800 |
Why?
|
| Aged | 111 | 2021 | 163280 | 0.780 |
Why?
|
| Aged, 80 and over | 58 | 2021 | 57776 | 0.740 |
Why?
|
| Bone Diseases | 4 | 2010 | 416 | 0.740 |
Why?
|
| Castration | 4 | 2013 | 159 | 0.730 |
Why?
|
| Spinal Fractures | 3 | 2011 | 696 | 0.710 |
Why?
|
| Radium | 3 | 2019 | 65 | 0.710 |
Why?
|
| Neoplasm Metastasis | 21 | 2019 | 4851 | 0.710 |
Why?
|
| Androgens | 12 | 2022 | 1281 | 0.690 |
Why?
|
| Cardiovascular Diseases | 19 | 2015 | 15165 | 0.690 |
Why?
|
| Bone Remodeling | 8 | 2016 | 575 | 0.670 |
Why?
|
| Collagen Type I | 7 | 2016 | 592 | 0.610 |
Why?
|
| Humans | 202 | 2022 | 744343 | 0.600 |
Why?
|
| Disease-Free Survival | 16 | 2018 | 6895 | 0.600 |
Why?
|
| Antibodies, Monoclonal | 9 | 2011 | 9274 | 0.590 |
Why?
|
| Diabetes Complications | 3 | 2013 | 1359 | 0.530 |
Why?
|
| Oligopeptides | 2 | 2011 | 1189 | 0.520 |
Why?
|
| Pyrazoles | 2 | 2021 | 1972 | 0.520 |
Why?
|
| Osteoblasts | 5 | 2013 | 1166 | 0.510 |
Why?
|
| Fractures, Spontaneous | 5 | 2015 | 230 | 0.510 |
Why?
|
| Middle Aged | 83 | 2021 | 213383 | 0.510 |
Why?
|
| Flutamide | 4 | 2015 | 96 | 0.510 |
Why?
|
| Diabetes Mellitus | 8 | 2014 | 5751 | 0.500 |
Why?
|
| Neoplastic Cells, Circulating | 8 | 2016 | 934 | 0.490 |
Why?
|
| Urogenital Neoplasms | 3 | 2012 | 137 | 0.480 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 1179 | 0.470 |
Why?
|
| Myostatin | 1 | 2014 | 124 | 0.450 |
Why?
|
| Digital Rectal Examination | 2 | 2012 | 42 | 0.450 |
Why?
|
| Insulin Resistance | 9 | 2013 | 3864 | 0.440 |
Why?
|
| Disease Progression | 24 | 2017 | 13284 | 0.430 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2016 | 5535 | 0.430 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2014 | 279 | 0.420 |
Why?
|
| Testosterone | 10 | 2017 | 2420 | 0.420 |
Why?
|
| Alkaline Phosphatase | 7 | 2014 | 865 | 0.400 |
Why?
|
| Prostate | 5 | 2015 | 1774 | 0.390 |
Why?
|
| Benzamides | 5 | 2017 | 1379 | 0.390 |
Why?
|
| Treatment Outcome | 39 | 2017 | 63114 | 0.380 |
Why?
|
| Acute Kidney Injury | 2 | 2013 | 1972 | 0.380 |
Why?
|
| Androstenes | 5 | 2015 | 170 | 0.380 |
Why?
|
| Sarcopenia | 2 | 2013 | 368 | 0.370 |
Why?
|
| Kallikreins | 3 | 2017 | 258 | 0.370 |
Why?
|
| Thiazolidinediones | 2 | 2004 | 476 | 0.360 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2006 | 129 | 0.350 |
Why?
|
| Absorptiometry, Photon | 5 | 2012 | 1725 | 0.350 |
Why?
|
| Peptides | 8 | 2016 | 4409 | 0.350 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2014 | 1660 | 0.350 |
Why?
|
| Metabolic Diseases | 2 | 2014 | 658 | 0.350 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2014 | 417 | 0.350 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 664 | 0.340 |
Why?
|
| Quality of Life | 6 | 2021 | 12804 | 0.340 |
Why?
|
| Taxoids | 8 | 2016 | 666 | 0.340 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 578 | 0.330 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2004 | 871 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2016 | 9239 | 0.320 |
Why?
|
| Hormone Antagonists | 1 | 2008 | 108 | 0.320 |
Why?
|
| Body Mass Index | 6 | 2014 | 12720 | 0.320 |
Why?
|
| Vaccines, DNA | 1 | 2009 | 305 | 0.310 |
Why?
|
| Veterans | 2 | 2012 | 2519 | 0.300 |
Why?
|
| Pyrrolidines | 2 | 2006 | 342 | 0.300 |
Why?
|
| Obesity | 6 | 2013 | 12745 | 0.290 |
Why?
|
| Clinical Trials as Topic | 12 | 2013 | 7913 | 0.280 |
Why?
|
| Androstadienes | 3 | 2013 | 346 | 0.280 |
Why?
|
| Injections, Subcutaneous | 3 | 2013 | 666 | 0.270 |
Why?
|
| Steroids | 2 | 2012 | 930 | 0.270 |
Why?
|
| Osteoblastoma | 1 | 2005 | 24 | 0.270 |
Why?
|
| Adipokines | 1 | 2008 | 319 | 0.260 |
Why?
|
| Incidence | 15 | 2015 | 20947 | 0.260 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 3772 | 0.260 |
Why?
|
| Metabolome | 1 | 2012 | 895 | 0.260 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 1801 | 0.260 |
Why?
|
| Estramustine | 2 | 2005 | 35 | 0.260 |
Why?
|
| Survival Rate | 14 | 2016 | 12788 | 0.250 |
Why?
|
| Time Factors | 19 | 2017 | 40075 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2019 | 6538 | 0.250 |
Why?
|
| Proportional Hazards Models | 13 | 2015 | 12354 | 0.240 |
Why?
|
| Placebos | 5 | 2014 | 1676 | 0.240 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 320 | 0.240 |
Why?
|
| Spinal Cord | 1 | 2012 | 1809 | 0.240 |
Why?
|
| Watchful Waiting | 3 | 2015 | 492 | 0.240 |
Why?
|
| Fatigue | 2 | 2008 | 1531 | 0.220 |
Why?
|
| Risk Factors | 22 | 2017 | 72290 | 0.220 |
Why?
|
| Signal Transduction | 4 | 2017 | 23403 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2012 | 11725 | 0.210 |
Why?
|
| Salvage Therapy | 3 | 2016 | 1275 | 0.210 |
Why?
|
| Lipids | 3 | 2008 | 3305 | 0.210 |
Why?
|
| Administration, Oral | 4 | 2017 | 3913 | 0.210 |
Why?
|
| Chromans | 1 | 2002 | 122 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 4 | 2017 | 1677 | 0.210 |
Why?
|
| Exercise Therapy | 1 | 2009 | 906 | 0.210 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2017 | 841 | 0.210 |
Why?
|
| Neoplasm Staging | 9 | 2016 | 11031 | 0.200 |
Why?
|
| Adipose Tissue | 4 | 2014 | 3279 | 0.200 |
Why?
|
| Prospective Studies | 17 | 2014 | 53288 | 0.190 |
Why?
|
| Endocrinology | 1 | 2007 | 443 | 0.190 |
Why?
|
| Follow-Up Studies | 15 | 2017 | 39050 | 0.190 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2004 | 624 | 0.190 |
Why?
|
| Indazoles | 1 | 2022 | 289 | 0.180 |
Why?
|
| Adult | 31 | 2022 | 214055 | 0.180 |
Why?
|
| SEER Program | 5 | 2014 | 1508 | 0.180 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2004 | 3143 | 0.170 |
Why?
|
| Drug Administration Schedule | 6 | 2014 | 4933 | 0.170 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 3 | 2014 | 98 | 0.170 |
Why?
|
| Vinblastine | 1 | 2000 | 502 | 0.170 |
Why?
|
| Clodronic Acid | 2 | 2012 | 60 | 0.170 |
Why?
|
| Cholesterol | 1 | 2008 | 2917 | 0.170 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 4931 | 0.170 |
Why?
|
| Kidney Neoplasms | 4 | 2012 | 4262 | 0.170 |
Why?
|
| Aromatase Inhibitors | 1 | 2002 | 491 | 0.160 |
Why?
|
| Radiotherapy | 4 | 2011 | 1533 | 0.160 |
Why?
|
| Risk Assessment | 17 | 2012 | 23338 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2015 | 3479 | 0.160 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 3086 | 0.160 |
Why?
|
| Electric Impedance | 1 | 2002 | 729 | 0.160 |
Why?
|
| Drug Therapy, Combination | 4 | 2017 | 6489 | 0.160 |
Why?
|
| Complementary Therapies | 2 | 2004 | 486 | 0.160 |
Why?
|
| Bone Resorption | 4 | 2010 | 723 | 0.160 |
Why?
|
| Prednisolone | 1 | 2019 | 334 | 0.150 |
Why?
|
| Myocardial Infarction | 4 | 2012 | 11727 | 0.150 |
Why?
|
| Cell Proliferation | 1 | 2013 | 10481 | 0.150 |
Why?
|
| Receptors, Androgen | 2 | 2015 | 1058 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 7279 | 0.150 |
Why?
|
| Prognosis | 12 | 2015 | 29063 | 0.150 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2012 | 1541 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2017 | 9959 | 0.150 |
Why?
|
| Odds Ratio | 5 | 2015 | 9849 | 0.150 |
Why?
|
| Triazoles | 1 | 2002 | 911 | 0.140 |
Why?
|
| Sulfonamides | 1 | 2006 | 1938 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2017 | 5172 | 0.140 |
Why?
|
| Survival Analysis | 6 | 2012 | 10252 | 0.130 |
Why?
|
| Multivariate Analysis | 4 | 2012 | 12245 | 0.130 |
Why?
|
| Thiazoles | 1 | 2002 | 1483 | 0.130 |
Why?
|
| Cohort Studies | 10 | 2016 | 40561 | 0.120 |
Why?
|
| Body Weight | 2 | 2010 | 4669 | 0.120 |
Why?
|
| Radionuclide Imaging | 3 | 2014 | 2031 | 0.120 |
Why?
|
| Osteocalcin | 3 | 2008 | 273 | 0.120 |
Why?
|
| Procollagen | 2 | 2011 | 185 | 0.120 |
Why?
|
| Gynecomastia | 1 | 2014 | 88 | 0.120 |
Why?
|
| Androstenols | 2 | 2010 | 25 | 0.120 |
Why?
|
| Piperidines | 1 | 2022 | 1602 | 0.110 |
Why?
|
| Transcription Factors | 2 | 2004 | 12208 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2009 | 5221 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2006 | 2788 | 0.110 |
Why?
|
| Enzyme Inhibitors | 3 | 2003 | 3798 | 0.110 |
Why?
|
| Samarium | 1 | 2012 | 3 | 0.110 |
Why?
|
| 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 1 | 2012 | 4 | 0.110 |
Why?
|
| Carcinoma | 2 | 2016 | 2375 | 0.110 |
Why?
|
| Bile Duct Diseases | 1 | 2013 | 100 | 0.110 |
Why?
|
| United States | 15 | 2014 | 69872 | 0.110 |
Why?
|
| Estradiol | 3 | 2007 | 2020 | 0.110 |
Why?
|
| DNA Repair | 1 | 2022 | 2046 | 0.110 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2012 | 136 | 0.110 |
Why?
|
| Forecasting | 2 | 2016 | 2951 | 0.110 |
Why?
|
| Pyrroles | 3 | 2014 | 1146 | 0.110 |
Why?
|
| Retrospective Studies | 17 | 2017 | 77449 | 0.100 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2007 | 548 | 0.100 |
Why?
|
| Hydroxybutyrates | 1 | 2012 | 82 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2004 | 2872 | 0.100 |
Why?
|
| Comorbidity | 3 | 2012 | 10388 | 0.100 |
Why?
|
| Acid Phosphatase | 1 | 2011 | 143 | 0.100 |
Why?
|
| Hot Flashes | 1 | 2014 | 317 | 0.100 |
Why?
|
| Risk | 3 | 2014 | 9687 | 0.100 |
Why?
|
| Wnt Proteins | 1 | 2015 | 721 | 0.100 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2004 | 144 | 0.100 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2012 | 126 | 0.100 |
Why?
|
| Femur | 2 | 2012 | 1297 | 0.100 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 817 | 0.090 |
Why?
|
| Indoles | 3 | 2014 | 1839 | 0.090 |
Why?
|
| Hip | 1 | 2012 | 257 | 0.090 |
Why?
|
| Algorithms | 2 | 2010 | 13881 | 0.090 |
Why?
|
| Depression | 2 | 2008 | 7766 | 0.090 |
Why?
|
| Calcium, Dietary | 2 | 2004 | 526 | 0.090 |
Why?
|
| Bile Acids and Salts | 1 | 2012 | 367 | 0.090 |
Why?
|
| Epidemiologic Methods | 3 | 2010 | 1364 | 0.090 |
Why?
|
| Breast Neoplasms | 8 | 2011 | 20822 | 0.090 |
Why?
|
| Haplotypes | 1 | 2016 | 2779 | 0.090 |
Why?
|
| Models, Biological | 2 | 2017 | 9583 | 0.080 |
Why?
|
| Leg | 1 | 2014 | 1116 | 0.080 |
Why?
|
| Hypogonadism | 2 | 2008 | 799 | 0.080 |
Why?
|
| Muscle Proteins | 1 | 2014 | 1159 | 0.080 |
Why?
|
| Ultraviolet Rays | 1 | 2013 | 1060 | 0.080 |
Why?
|
| Glucocorticoids | 2 | 2015 | 2107 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 10943 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2009 | 13102 | 0.080 |
Why?
|
| Fractures, Malunited | 1 | 2008 | 82 | 0.080 |
Why?
|
| Isoenzymes | 1 | 2011 | 1726 | 0.070 |
Why?
|
| Hyperaldosteronism | 1 | 2010 | 240 | 0.070 |
Why?
|
| Lumbar Vertebrae | 2 | 2009 | 1848 | 0.070 |
Why?
|
| Pain | 3 | 2014 | 4986 | 0.070 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 2187 | 0.070 |
Why?
|
| Kinetics | 2 | 2015 | 6473 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2014 | 2617 | 0.070 |
Why?
|
| DNA Damage | 1 | 2016 | 2432 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2886 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2012 | 2618 | 0.070 |
Why?
|
| Estrogens | 2 | 2003 | 1566 | 0.070 |
Why?
|
| Urologic Diseases | 1 | 2008 | 244 | 0.070 |
Why?
|
| DNA, Antisense | 1 | 2005 | 46 | 0.070 |
Why?
|
| Advisory Committees | 1 | 2010 | 775 | 0.070 |
Why?
|
| Neoplasms | 3 | 2009 | 21683 | 0.070 |
Why?
|
| Coronary Disease | 2 | 2012 | 6077 | 0.060 |
Why?
|
| Radiopharmaceuticals | 2 | 2012 | 2645 | 0.060 |
Why?
|
| Depressive Disorder, Major | 1 | 2002 | 4644 | 0.060 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2008 | 360 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2012 | 2455 | 0.060 |
Why?
|
| Infusions, Intravenous | 2 | 2007 | 2274 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2010 | 719 | 0.060 |
Why?
|
| Microarray Analysis | 1 | 2007 | 767 | 0.060 |
Why?
|
| Spine | 1 | 2012 | 1144 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 1351 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2016 | 2899 | 0.060 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 1978 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2017 | 424 | 0.060 |
Why?
|
| Diethylstilbestrol | 1 | 2004 | 93 | 0.060 |
Why?
|
| Receptors, Growth Factor | 1 | 2005 | 334 | 0.060 |
Why?
|
| Diagnostic Imaging | 3 | 2014 | 3507 | 0.060 |
Why?
|
| Cross-Sectional Studies | 5 | 2008 | 25043 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 1889 | 0.060 |
Why?
|
| Ureteral Neoplasms | 1 | 2004 | 111 | 0.060 |
Why?
|
| Antimetabolites | 1 | 2003 | 125 | 0.060 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 15540 | 0.060 |
Why?
|
| Age Factors | 3 | 2016 | 18370 | 0.060 |
Why?
|
| Drug Contamination | 1 | 2004 | 147 | 0.060 |
Why?
|
| Female | 22 | 2016 | 380194 | 0.050 |
Why?
|
| Glucose Tolerance Test | 1 | 2006 | 1150 | 0.050 |
Why?
|
| Lymphatic Metastasis | 3 | 2012 | 2924 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2011 | 6459 | 0.050 |
Why?
|
| Hemoglobins | 2 | 2014 | 1534 | 0.050 |
Why?
|
| Adolescent | 2 | 2022 | 85781 | 0.050 |
Why?
|
| Biopsy | 2 | 2011 | 6756 | 0.050 |
Why?
|
| Edema | 1 | 2006 | 789 | 0.050 |
Why?
|
| Adiponectin | 1 | 2008 | 1100 | 0.050 |
Why?
|
| Osteogenesis | 1 | 2009 | 1299 | 0.050 |
Why?
|
| Multiple Myeloma | 3 | 2009 | 5181 | 0.050 |
Why?
|
| Survivors | 2 | 2012 | 2291 | 0.050 |
Why?
|
| Cell Separation | 1 | 2007 | 1751 | 0.050 |
Why?
|
| Serenoa | 1 | 2001 | 11 | 0.050 |
Why?
|
| Causality | 1 | 2008 | 1275 | 0.050 |
Why?
|
| Alendronate | 1 | 2003 | 171 | 0.050 |
Why?
|
| Syndrome | 1 | 2008 | 3251 | 0.050 |
Why?
|
| Carboplatin | 1 | 2005 | 801 | 0.050 |
Why?
|
| Dyslipidemias | 1 | 2009 | 849 | 0.050 |
Why?
|
| Neutrophils | 1 | 2014 | 3719 | 0.050 |
Why?
|
| Flushing | 1 | 2001 | 49 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 2008 | 1814 | 0.050 |
Why?
|
| Hypericum | 1 | 2001 | 58 | 0.050 |
Why?
|
| Anthropometry | 1 | 2006 | 1350 | 0.050 |
Why?
|
| Peripheral Arterial Disease | 1 | 2012 | 1188 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 2727 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2005 | 720 | 0.050 |
Why?
|
| Acupuncture | 1 | 2001 | 90 | 0.050 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2003 | 520 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2008 | 1180 | 0.050 |
Why?
|
| Boronic Acids | 1 | 2005 | 965 | 0.050 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2003 | 365 | 0.050 |
Why?
|
| Deoxycytidine | 1 | 2004 | 826 | 0.050 |
Why?
|
| Weight Gain | 1 | 2010 | 2292 | 0.050 |
Why?
|
| Animals | 6 | 2015 | 168757 | 0.050 |
Why?
|
| Triglycerides | 1 | 2008 | 2454 | 0.050 |
Why?
|
| Coronary Artery Disease | 2 | 2010 | 6487 | 0.040 |
Why?
|
| Thalidomide | 1 | 2005 | 890 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 1956 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 1770 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 1170 | 0.040 |
Why?
|
| Rats | 2 | 2008 | 24260 | 0.040 |
Why?
|
| Vitamin D | 1 | 2013 | 3223 | 0.040 |
Why?
|
| Anticarcinogenic Agents | 1 | 2001 | 253 | 0.040 |
Why?
|
| Pelvic Bones | 1 | 2001 | 265 | 0.040 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 1671 | 0.040 |
Why?
|
| Gene Expression | 1 | 2012 | 7799 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2009 | 5078 | 0.040 |
Why?
|
| Pyrazines | 1 | 2005 | 1230 | 0.040 |
Why?
|
| Phytotherapy | 1 | 2001 | 298 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2011 | 5097 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 13989 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2002 | 8324 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2008 | 2356 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2001 | 629 | 0.040 |
Why?
|
| Dyspnea | 1 | 2006 | 1303 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 14722 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2005 | 4445 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 968 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2010 | 2265 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2010 | 3743 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2002 | 712 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2017 | 1654 | 0.040 |
Why?
|
| Ketoconazole | 2 | 2010 | 95 | 0.040 |
Why?
|
| Plant Extracts | 1 | 2001 | 471 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 3674 | 0.040 |
Why?
|
| Health Promotion | 1 | 2010 | 2205 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 8642 | 0.040 |
Why?
|
| Prostatic Hyperplasia | 1 | 2001 | 523 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2012 | 2245 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2002 | 878 | 0.040 |
Why?
|
| Erythropoietin | 1 | 2001 | 726 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 3778 | 0.030 |
Why?
|
| Health Status | 1 | 2009 | 4034 | 0.030 |
Why?
|
| Cell Division | 1 | 2003 | 4568 | 0.030 |
Why?
|
| Inflammation | 2 | 2014 | 10638 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2007 | 15076 | 0.030 |
Why?
|
| Canada | 2 | 2013 | 2065 | 0.030 |
Why?
|
| Collagen | 1 | 2004 | 2689 | 0.030 |
Why?
|
| Osteolysis | 2 | 2007 | 270 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2002 | 2879 | 0.030 |
Why?
|
| Food-Drug Interactions | 1 | 2014 | 27 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 2029 | 0.030 |
Why?
|
| Gossypol | 1 | 2014 | 23 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 4776 | 0.030 |
Why?
|
| Densitometry | 2 | 2004 | 156 | 0.030 |
Why?
|
| Biological Availability | 1 | 2014 | 397 | 0.030 |
Why?
|
| Morbidity | 2 | 2010 | 1769 | 0.030 |
Why?
|
| Boston | 1 | 2007 | 9313 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 610 | 0.030 |
Why?
|
| Radioisotopes | 1 | 2015 | 499 | 0.030 |
Why?
|
| Pain Measurement | 2 | 2014 | 3420 | 0.030 |
Why?
|
| Cell Survival | 1 | 2003 | 5882 | 0.030 |
Why?
|
| Michigan | 1 | 2014 | 350 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2003 | 2038 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2008 | 8554 | 0.030 |
Why?
|
| Disease Management | 1 | 2003 | 2459 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 399 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 793 | 0.030 |
Why?
|
| Radiography | 2 | 2014 | 7023 | 0.030 |
Why?
|
| Anemia | 1 | 2001 | 1506 | 0.030 |
Why?
|
| Vitamin D Deficiency | 1 | 2001 | 1343 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2004 | 2376 | 0.020 |
Why?
|
| Sunlight | 1 | 2013 | 325 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2006 | 6256 | 0.020 |
Why?
|
| Life Style | 1 | 2003 | 3835 | 0.020 |
Why?
|
| Insulin | 1 | 2006 | 6580 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 3870 | 0.020 |
Why?
|
| RNA Splicing | 1 | 2015 | 907 | 0.020 |
Why?
|
| Urothelium | 1 | 2012 | 277 | 0.020 |
Why?
|
| American Cancer Society | 1 | 2010 | 61 | 0.020 |
Why?
|
| Australia | 1 | 2013 | 1170 | 0.020 |
Why?
|
| California | 1 | 2014 | 1402 | 0.020 |
Why?
|
| Stroke | 1 | 2012 | 9981 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 464 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 599 | 0.020 |
Why?
|
| Calcium | 1 | 2003 | 5756 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2012 | 690 | 0.020 |
Why?
|
| Brachytherapy | 2 | 2010 | 1248 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 552 | 0.020 |
Why?
|
| Fasting | 1 | 2014 | 1593 | 0.020 |
Why?
|
| Mutation | 2 | 2016 | 29786 | 0.020 |
Why?
|
| Nomograms | 1 | 2010 | 228 | 0.020 |
Why?
|
| Age Distribution | 2 | 2004 | 2902 | 0.020 |
Why?
|
| Isoleucine | 1 | 2007 | 112 | 0.020 |
Why?
|
| Hawaii | 1 | 2007 | 105 | 0.020 |
Why?
|
| Osteoprotegerin | 1 | 2008 | 176 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 2003 | 4251 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 16689 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 3557 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 2012 | 0.020 |
Why?
|
| Sialoglycoproteins | 1 | 2008 | 318 | 0.020 |
Why?
|
| Threonine | 1 | 2007 | 279 | 0.020 |
Why?
|
| Histidine | 1 | 2007 | 313 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 3339 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2014 | 2017 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2012 | 972 | 0.020 |
Why?
|
| Leucine | 1 | 2007 | 561 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2014 | 1058 | 0.020 |
Why?
|
| Proline | 1 | 2007 | 458 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2008 | 15295 | 0.020 |
Why?
|
| Prevalence | 1 | 2002 | 15226 | 0.020 |
Why?
|
| American Heart Association | 1 | 2010 | 1056 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 1420 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2015 | 2183 | 0.020 |
Why?
|
| Estradiol Congeners | 1 | 2004 | 28 | 0.020 |
Why?
|
| Mitoxantrone | 1 | 2005 | 152 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2010 | 1184 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2016 | 3086 | 0.020 |
Why?
|
| Palliative Care | 2 | 2014 | 3493 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 1915 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 20129 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2007 | 2050 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 2418 | 0.010 |
Why?
|
| Ethinyl Estradiol | 1 | 2004 | 116 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2010 | 1261 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2013 | 1859 | 0.010 |
Why?
|
| Tyrosine | 1 | 2007 | 1461 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2010 | 1184 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2014 | 2728 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 4554 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 7785 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2010 | 1167 | 0.010 |
Why?
|
| Finasteride | 1 | 2003 | 90 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 892 | 0.010 |
Why?
|
| Microfluidics | 1 | 2007 | 662 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2012 | 3200 | 0.010 |
Why?
|
| Creatinine | 1 | 2007 | 1919 | 0.010 |
Why?
|
| Age of Onset | 1 | 2007 | 3271 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 3508 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2007 | 3588 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2007 | 1788 | 0.010 |
Why?
|
| Patient Selection | 1 | 2012 | 4215 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 4186 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2007 | 2564 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2007 | 21746 | 0.010 |
Why?
|
| Registries | 1 | 2014 | 8089 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3610 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 1708 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 4982 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2002 | 745 | 0.010 |
Why?
|
| Warfarin | 1 | 2004 | 1496 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2010 | 7729 | 0.010 |
Why?
|
| Mass Screening | 1 | 2009 | 5255 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 13408 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2004 | 4599 | 0.010 |
Why?
|
| Kidney | 1 | 2004 | 7186 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 81183 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 56430 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 19905 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 17446 | 0.000 |
Why?
|